Clinical effectiveness of magnesium orotate in patients with cardiac arrhythmias, arterial hypertension, and mitral valve prolapse
| Autor: | E. V. Akatova, O. P. Nikolin, A. I. Martynov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2009 |
| Předmět: | |
| Zdroj: | Кардиоваскулярная терапия и профилактика, Vol 8, Iss 8, Pp 9-12 (2009) |
| Druh dokumentu: | article |
| ISSN: | 1728-8800 2619-0125 |
| Popis: | Aim. To evaluate the effectiveness of magnesium orotate in the patients with cardiac arrhythmias, arterial hypertension (AH), and idiopathic mitral valve prolapse (MVP). Material and methods. The complex examination, dynamic follow-up, and placebo-controlled differentiated treatment were performed in 84 patients with idiopathic MVP. All participants underwent echocardiography, 24-hour blood pressure monitoring (BPM) and electrocardiography (ECG) monitoring, office BP measurement, spectral analysis of heart rate variability (HRV), and physical stress test. The main group (MG; n=43) received magnesium orotate (3000 mg/d) for 6 months; the comparison group (CG; n=41) received placebo. Results. According to the 24-hour ECG monitoring data, the treatment was associated with disappearance of high-grade arrhythmias and a 40% reduction in supraventricular (paroxysmal and non-paroxysmal) tachycardia incidence. The number of ventricular extrasystoles was reduced in 26%, and they disappeared in 54%. In 8%, polytopic ventricular extrasystoles were substituted by occasional monotopic extrasystoles. These changes were not observed in the CG patients. The percentage of Stage I AH patients decreased from 38% to 8% in the MG, and from 30% to 20% in the CG. Conclusion. In MVP patients, magnesium orotate treatment improved electro-physiological heart parameters, with reduced supraventricular and ventricular extrasystole incidence and improved circadian BP profile. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|